Patents Represented by Attorney Garth C. Butterfield

Find this attorney in the Justia Lawyer Directory

  • Preparation of substituted piperidenes
    Patent number: 5663349
    Abstract: Novel processes are disclosed for the preparation and resolution of substituted piperidines of the formula ##STR1## wherein R.sup.1 and R.sup.2 are defined as below, and related compounds, as well as novel intermediates used in such processes.
    Type: Grant
    Filed: July 12, 1994
    Date of Patent: September 2, 1997
    Assignee: Pfizer Inc
    Inventors: Terry J. Rosen, Dennis M. Godek, Sally Gut, Lewin Wint
  • Substituted hexahdryoazepinones and tetrahydrobenzazepinones
    Patent number: 5643904
    Abstract: The present invention relates to novel substituted hexahydroazepinones and tetrahydrobenzazepinones of the formulae ##STR1## wherein R.sup.1, Z.sup.1, Z.sup.2, W.sup.1, W.sup.2, Y.sup.1 and Y.sup.2 are as defined below, and to novel intermediates used in the synthesis of such compounds.Such compounds are useful in the treatment and prevention of gastrointestinal disorders, pain and anxiety disorders.
    Type: Grant
    Filed: June 27, 1995
    Date of Patent: July 1, 1997
    Assignee: Pfizer Inc.
    Inventor: John A. Lowe, III
  • .beta..sub.3 -Adrenoceptor agonists and antagonists for the treatment of intestinal motility disorders, depression, prostate disease and dyslipidemia
    Patent number: 5627200
    Abstract: This invention relates to methods for treating intestinal motility disorders, intestinal ulcerations, including inflammatory bowel disease, ulcerative colitis, Crohn's disease and proctitis, and gastrointestinal ulcerations, depression, prostate disease and dyslipidemia by administering a .beta..sub.3 -adrenoceptor antagonist or agonist.
    Type: Grant
    Filed: September 26, 1994
    Date of Patent: May 6, 1997
    Assignee: Pfizer Inc
    Inventors: David K. Kreutter, Robert L. Dow
  • Muscarinic receptor antagonists
    Patent number: 5607950
    Abstract: The invetion is a method of treating irritable bowel syndrome with a compound selected from the formula ##STR1## wherein R, R.sup.1, m, n p are as defined in the specification, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: February 10, 1994
    Date of Patent: March 4, 1997
    Assignee: Pfizer Inc.
    Inventors: David Alker, Peter E. Cross, Alexander R. Mackenzie
  • Endo-bicyclo[2.2.1]heptan-2-ol and derived pharmaceutical agents
    Patent number: 5395935
    Abstract: An optically active compound selected from the group consisting of a compound having the absolute stereochemical formula ##STR1## and a compound having the absolute stereochemical formula ##STR2## and intermediates thereof.
    Type: Grant
    Filed: October 12, 1993
    Date of Patent: March 7, 1995
    Assignee: Pfizer Inc.
    Inventor: Nicholas A. Saccomano
  • Benzazabicyclic carbamates as novel cholinesterase inhibitors
    Patent number: 5387590
    Abstract: Compounds of the formula ##STR1## wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, X, m, n, o, p, q and r are as defined below. The compounds are memory enhancing cholinesterase inhibitors useful in enhancing memory, novel intermediates used in their synthesis, and analgesic agents.
    Type: Grant
    Filed: February 28, 1992
    Date of Patent: February 7, 1995
    Assignee: Pfizer Inc.
    Inventor: Yuhpyng L. Chen
  • Substituted sulfonamides and related compounds in the treatment of asthma, arthritis and related diseases
    Patent number: 5384318
    Abstract: Compounds of the formula ##STR1## and pharmaceutical compositions comprising them, wherein R.sup.1, R.sup.2, R.sup.3, W, X and Z are as defined below. The compounds are inhibitors of 5-lipoxygenase enzyme and antagonists of leukotriene B4, leukotriene C4, leukotriene D4 and leukotriene E4.
    Type: Grant
    Filed: February 21, 1992
    Date of Patent: January 24, 1995
    Assignee: Pfizer Inc.
    Inventors: James F. Eggler, Anthony Marfat, Lawrence S. Melvin, Jr., Hiroko Masamune